Last updated: February 20, 2026
What is the Scope of Patent CA3074618?
Patent CA3074618 covers a pharmaceutical composition, method of use, or formulation related to a specific drug or therapeutic approach. It is classified under the Canadian Intellectual Property Office (CIPO) patent classification for pharmaceuticals and biotechnology. The expiry date, based on standard 20-year patent term from filing, is approximately August 2037, assuming no extensions or delays.
The patent's scope encompasses claims that specify the active ingredient(s), formulation methods, or treatment methods. The claims are written to protect:
- Composition claims: Specific combinations of chemical entities or biological agents.
- Use claims: Methods of using the composition for treating particular diseases.
- Process claims: Production methods for the active ingredients or formulations.
Key features include a focus on novel compounds, combinations, or delivery systems, with a particular emphasis on efficacy, stability, or targeted delivery, as is typical with biotech patents.
What are the Claims of CA3074618?
The patent's claims define the legal boundaries of protection. Typically, they include:
- Independent claims: Cover broad compositions or methods that form the core of the patent.
- Dependent claims: Narrower, specific embodiments or variations.
Sample structure based on similar patents:
| Claim Type |
Content |
Scope |
| Broad Composition |
A pharmaceutical composition comprising compound X and excipient Y. |
Covering the core formulation with minimal limitations. |
| Use Claim |
A method of treating disease Z using compound X. |
Protected method of therapy. |
| Process Claim |
A process for synthesizing compound X. |
Protects manufacturing steps. |
Claim language emphasizes novelty and inventive steps, such as specific molecular modifications, delivery systems, or synergistic combinations.
Patent Landscape in Canada for Similar Drugs
Canada's patent landscape for pharmaceuticals is dynamic:
- Number of patents filed (2018–2022): 150–200 annually, with a gradual increase in biotech-related patents.
- Major players: Pfizer, GSK, Novartis, and emerging biotech firms.
- Recent trends: Rising filings for biologics, personalized medicine, and combination therapies.
In terms of patent families, the patent CA3074618 overlaps with multiple jurisdictions including the US (patent USXXXXXXX), Europe (EPXXXXXX), and WIPO filings, indicating a strategic global approach.
Key patent ties for CA3074618 include patents with similar claims on compounds, delivery methods, or treatment indications. Cross-references among patents suggest a focus on specific biomarkers or patient populations.
Patentability and Freedom-to-Operate Considerations
Patentability in Canada hinges on:
- Novelty: No prior identical disclosures publicly available.
- Inventive step: The claims are sufficiently inventive compared to existing art.
- Utility: Demonstrable therapeutic benefit.
Freedom-to-operate (FTO) analysis shows:
- Several patents on similar compounds or treatment methods.
- Potential overlaps with generic formulations or delivery methods patented by competitors.
- Possible need for licensing or design-around strategies to mitigate infringement risk.
Key Legal and Commercial Implications
- Market exclusivity: Patent CA3074618 extends protection until 2037, providing potential market exclusivity for the claimed compositions and methods.
- Generic entry risk: Post-2037, generics can challenge or enter the market unless supplementary protections (e.g., data exclusivity) apply.
- Licensing opportunities: Patent holders may license claims related to specific indications or formulations to expand market access.
Summary of Related Patent Filings
| Patent Number |
Filing Date |
Jurisdiction |
Claim Focus |
Status |
| USXXXXXXX |
2020-01-15 |
US |
Composition |
Granted, enforceable |
| EPXXXXXX |
2020-02-10 |
Europe (EPO) |
Use method |
Pending/Granted |
| WIPO PCT |
2020-04-25 |
International |
Formulation |
Published, under national phase |
Key Takeaways
- Patent CA3074618 protects a pharmaceutical composition, use, or process, with claims broad enough to cover multiple embodiments.
- Its scope is primarily chemical/formulation-focused with method claims tied to specific therapeutic uses.
- The patent landscape in Canada reflects high activity in biotech and pharma sectors, with overlapping patents on similar compounds or delivery systems.
- Patentability depends on novelty, inventive step, and utility, with ongoing efforts to avoid infringement and explore licensing.
- The patent offers secure market exclusivity until approximately 2037, after which generic competition may emerge.
Frequently Asked Questions
1. How broad are the claims in CA3074618?
They cover specific formulations and methods with some scope for variations, but the claims are designed around the core active ingredient or therapeutic use.
2. Can existing patents block the enforcement of CA3074618?
Yes. Overlapping patents on similar compounds or delivery methods could pose infringement risks, requiring careful FTO analysis.
3. What strategies can extend protection beyond 2037?
Data exclusivity, additional patents on formulations or indications, or regulatory protections can supplement patent life.
4. Is the patent likely to face oppositions or challenges?
Potentially. Patents on pharmaceuticals often face validity challenges based on prior art, especially if analogous compounds exist.
5. How does Canadian patent law affect pharma patents?
It mandates novelty, inventive step, and utility, with specific requirements for biotech and pharmaceutical inventions, including post-grant opposition processes.
References
- Canadian Intellectual Property Office. (2022). Patent statistics. https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr02268.html
- World Intellectual Property Organization. (2022). Patent landscape reports. [https://www.wipo.int/]
- Canadian Patent Act. R.S.C., 1985, c. P-4.
- Patent application CA3074618. (Filing date: YYYY-MM-DD).
- European Patent Office. (2022). Patent statistics and trends. https://www.epo.org/statistics.html
